FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2918139659> ?p ?o ?g. }

• W2918139659 endingPage "2244" @default.
• W2918139659 startingPage "2244" @default.
• W2918139659 abstract "Abstract Oxidative stress (OS) has been demonstrated to play a central role in the pathophysiology of sickle cell disease (SCD). The antioxidant N -acetylcysteine (NAC) is an important precursor of cysteine, which is the rate limiting substrate for glutathione (GSH) synthesis, and can thereby exert intracellular antioxidant effects. Yet, because of its thiol group, NAC can also act extracellularly as a reducing agent to break protein disulfide bonds, or to scavenge reactive oxidants. Pilot studies with NAC in SCD have demonstrated various beneficial effects, reducing markers of red blood cell membrane damage, hemolysis and OS. The major plasma modulator of OS is the amino acid cysteine (Cys), with the ratio of its reduced form to the oxidized form reflecting the plasma redox state. Under oxidative stress, relatively low levels of free thiol Cys and high levels of protein bound Cys are observed (Fu et al. Blood 2015; 126:1044). The aim of this study was to assess the effects of oral NAC on the thiol redox balance in SCD patients. Moreover, we explored correlations of the thiol redox balance at baseline with other clinical and pathophysiological markers of SCD. Plasma was analyzed from 2 completed prospective studies that evaluated the effect of oral NAC in SCD: 1) an open label, uncontrolled, pilot study consisting of 6 weeks of NAC 1,200 -2,400mg daily, and 6 weeks follow-up in patients with HbSS or HbSβ⁰-disease (N=10, Nur et al. Ann Hematol. 2012; 91:1097-105); and 2) a randomized, placebo-controlled trial (RCT) of oral NAC 1,200mg daily for 6 months in HbSS, HbSC, HbSβ⁰ or HbSβ⁺ patients (N=96, Sins et al. Br J Haematol. 2017 ) . Using liquid chromatography-tandem mass-spectrometry, we assessed the following markers of the thiol redox balance: total NAC, total and free (reduced) Cys, and protein bound (oxidized) Cys. In both studies, oral NAC significantly increased levels of total NAC and free Cys, and decreased levels of protein bound Cys, as compared to baseline (figure 1). In the pilot study, total Cys was decreased as compared to baseline, however, no significant difference was observed in the RCT. In addition, when comparing the mean change from baseline of these parameters between the NAC arm and the placebo arm of the RCT, similar results were found. Yet, differences in mean change of protein bound and total Cys did not reach statistical significance in this analysis (results not shown). Multivariate linear regression analysis of baseline thiol redox values in the RCT was performed, adjusting for genotype and use of HU. In this analysis, higher levels of free Cys (less OS) were independently associated with a higher MCV (standardized β [sβ] 0.36, P In line with previous intravenous studies, oral treatment with NAC significantly improved the thiol plasma redox balance in patients with SCD. These effects appeared to be most apparent in the uncontrolled pilot study, possibly due to poor adherence and a relatively low dosage in the RCT. Nevertheless, these findings emphasize the role of NAC as an extracellular reducing agent of protein disulfide bonds, beyond acting as a substrate for glutathione synthesis or as a direct scavenger of reactive oxygen species. Moreover, a higher extracellular oxidant burden at baseline was independently associated with endothelial and coagulation activation, and with the number of hospital admissions. Thereby, we provide indirect evidence that improvement of the thiol redox balance may be an important therapeutic target in SCD, improving other pathophysiological processes of the disease, and potentially even reducing the number of hospital admissions. Hence, the use of NAC and other thiol antioxidants in SCD deserves further investigation. Download : Download high-res image (238KB) Download : Download full-size image Disclosures Rijneveld: Jazz pharmaceuticals: Research Funding; Pfizer: Membership on an entity's Board of Directors or advisory committees. Delannoy: Innate Pharma: Honoraria." @default.
• W2918139659 created "2019-03-02" @default.
• W2918139659 creator A5023743243 @default.
• W2918139659 creator A5027328497 @default.
• W2918139659 creator A5027749653 @default.
• W2918139659 creator A5029399368 @default.
• W2918139659 creator A5030574503 @default.
• W2918139659 creator A5030615530 @default.
• W2918139659 creator A5030734396 @default.
• W2918139659 creator A5033263313 @default.
• W2918139659 creator A5036916796 @default.
• W2918139659 creator A5038643808 @default.
• W2918139659 creator A5039558752 @default.
• W2918139659 creator A5040075184 @default.
• W2918139659 creator A5040844252 @default.
• W2918139659 creator A5044124435 @default.
• W2918139659 creator A5044154938 @default.
• W2918139659 creator A5048758283 @default.
• W2918139659 creator A5049097971 @default.
• W2918139659 creator A5057335043 @default.
• W2918139659 creator A5066022823 @default.
• W2918139659 creator A5068532565 @default.
• W2918139659 creator A5068744991 @default.
• W2918139659 creator A5079993239 @default.
• W2918139659 creator A5081794009 @default.
• W2918139659 creator A5084305622 @default.
• W2918139659 creator A5085380635 @default.
• W2918139659 creator A5091157753 @default.
• W2918139659 date "2017-12-07" @default.
• W2918139659 modified "2023-10-06" @default.
• W2918139659 title "Effects of Oral N -Acetylcysteine on Oxidative Stress in Patients with Sickle Cell Disease" @default.
• W2918139659 doi "https://doi.org/10.1182/blood.v130.suppl_1.2244.2244" @default.
• W2918139659 hasPublicationYear "2017" @default.
• W2918139659 type Work @default.
• W2918139659 sameAs 2918139659 @default.
• W2918139659 citedByCount "0" @default.
• W2918139659 crossrefType "journal-article" @default.
• W2918139659 hasAuthorship W2918139659A5023743243 @default.
• W2918139659 hasAuthorship W2918139659A5027328497 @default.
• W2918139659 hasAuthorship W2918139659A5027749653 @default.
• W2918139659 hasAuthorship W2918139659A5029399368 @default.
• W2918139659 hasAuthorship W2918139659A5030574503 @default.
• W2918139659 hasAuthorship W2918139659A5030615530 @default.
• W2918139659 hasAuthorship W2918139659A5030734396 @default.
• W2918139659 hasAuthorship W2918139659A5033263313 @default.
• W2918139659 hasAuthorship W2918139659A5036916796 @default.
• W2918139659 hasAuthorship W2918139659A5038643808 @default.
• W2918139659 hasAuthorship W2918139659A5039558752 @default.
• W2918139659 hasAuthorship W2918139659A5040075184 @default.
• W2918139659 hasAuthorship W2918139659A5040844252 @default.
• W2918139659 hasAuthorship W2918139659A5044124435 @default.
• W2918139659 hasAuthorship W2918139659A5044154938 @default.
• W2918139659 hasAuthorship W2918139659A5048758283 @default.
• W2918139659 hasAuthorship W2918139659A5049097971 @default.
• W2918139659 hasAuthorship W2918139659A5057335043 @default.
• W2918139659 hasAuthorship W2918139659A5066022823 @default.
• W2918139659 hasAuthorship W2918139659A5068532565 @default.
• W2918139659 hasAuthorship W2918139659A5068744991 @default.
• W2918139659 hasAuthorship W2918139659A5079993239 @default.
• W2918139659 hasAuthorship W2918139659A5081794009 @default.
• W2918139659 hasAuthorship W2918139659A5084305622 @default.
• W2918139659 hasAuthorship W2918139659A5085380635 @default.
• W2918139659 hasAuthorship W2918139659A5091157753 @default.
• W2918139659 hasConcept C10162356 @default.
• W2918139659 hasConcept C126322002 @default.
• W2918139659 hasConcept C181199279 @default.
• W2918139659 hasConcept C185592680 @default.
• W2918139659 hasConcept C2776151105 @default.
• W2918139659 hasConcept C2777847592 @default.
• W2918139659 hasConcept C2778004101 @default.
• W2918139659 hasConcept C2779201268 @default.
• W2918139659 hasConcept C2781324293 @default.
• W2918139659 hasConcept C2911203004 @default.
• W2918139659 hasConcept C3020296196 @default.
• W2918139659 hasConcept C538909803 @default.
• W2918139659 hasConcept C55493867 @default.
• W2918139659 hasConcept C71924100 @default.
• W2918139659 hasConcept C98274493 @default.
• W2918139659 hasConceptScore W2918139659C10162356 @default.
• W2918139659 hasConceptScore W2918139659C126322002 @default.
• W2918139659 hasConceptScore W2918139659C181199279 @default.
• W2918139659 hasConceptScore W2918139659C185592680 @default.
• W2918139659 hasConceptScore W2918139659C2776151105 @default.
• W2918139659 hasConceptScore W2918139659C2777847592 @default.
• W2918139659 hasConceptScore W2918139659C2778004101 @default.
• W2918139659 hasConceptScore W2918139659C2779201268 @default.
• W2918139659 hasConceptScore W2918139659C2781324293 @default.
• W2918139659 hasConceptScore W2918139659C2911203004 @default.
• W2918139659 hasConceptScore W2918139659C3020296196 @default.
• W2918139659 hasConceptScore W2918139659C538909803 @default.
• W2918139659 hasConceptScore W2918139659C55493867 @default.
• W2918139659 hasConceptScore W2918139659C71924100 @default.
• W2918139659 hasConceptScore W2918139659C98274493 @default.
• W2918139659 hasLocation W29181396591 @default.
• W2918139659 hasOpenAccess W2918139659 @default.
• W2918139659 hasPrimaryLocation W29181396591 @default.
• W2918139659 hasRelatedWork W1985249286 @default.
• W2918139659 hasRelatedWork W2005886538 @default.

• next